Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis

Version 1 : Received: 26 July 2022 / Approved: 27 July 2022 / Online: 27 July 2022 (13:29:14 CEST)

How to cite: Alicandro, G.; Daccò, V.; Cariani, L.; Rosazza, C.; Sciarrabba, C. S.; Ferraro, F.; Lanfranchi, C.; Medino, P.; Girelli, D.; Colombo, C. Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis. Preprints 2022, 2022070422. https://doi.org/10.20944/preprints202207.0422.v1 Alicandro, G.; Daccò, V.; Cariani, L.; Rosazza, C.; Sciarrabba, C. S.; Ferraro, F.; Lanfranchi, C.; Medino, P.; Girelli, D.; Colombo, C. Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis. Preprints 2022, 2022070422. https://doi.org/10.20944/preprints202207.0422.v1

Abstract

During the SARS-CoV-2 vaccination campaign, people with CF (pwCF) were considered a clinically vulnerable population. However, data on immunogenicity of anti-SARS-CoV-2 vaccines in pwCF are lacking. We conducted a prospective study enrolling all patients aged >12 and followed-up in our CF centre, who received two doses of the BNT162b2 vaccine in March-­­­October 2021. They underwent a blood sample for quantification of antibodies to the SARS-CoV-2 spike protein receptor binding domain immediately before receiving the first dose and after 3 and 6 months from the second dose. We enrolled 143 patients (median age: 21 years, range: 13-38); of whom 16 had a previous infection. Median antibody titer (interquartile range) after 3 months from vaccination was 1288 U/mL (730-2115) and decreased to 918 U/mL (534-1488) after 6 months (P<0.0001). Median values were higher among previously infected patients as compared to those naïve to SARS-CoV-2 (9107 vs 1229 U/mL at 3 months and 4810 vs 829 U/mL at 6 months, P<0.0001) with no significant differences in the rate of decline over time (P=0.135). All pwCF mounted an antibody response after two-doses of BNT162b2 vaccine that waned at 6 months from vaccination. Age ≥30 years and use of inhaled corticosteroids were associated with a lower humoral response.

Keywords

cystic fibrosis; SARS-CoV-2; Covid-19, vaccine; antibody response; humoral response

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.